Citations

Mayo Clinic

Clear

102 citation(s) found for "Cullen, L".

Ultrasound Is a Sensitive Technique to Detect Fasciculations of Cranial Muscles in Amyotrophic Lateral Sclerosis (ALS) (P5.014)
Kassardjian, Charles D. , Baria, Michael R. , Weikamp, Janneke G. , Boon, Andrea J. , O’Gorman, Cullen , Alfen, Nens van

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.p5.014 Get It

Progressive Autoimmune Neuromyotonia with Low Voltage-Gated Potassium Channel-Complex IgG and CASPR2-IgG Following Remote Inflammatory Polyradiculoneuropathy (P4.019)
Linnoila, Jenny, Kassardjian, Charles D. , Litchy, William J. , Milone, Margherita , Lennon, Vanda A. , O’Gorman, Cullen , Staff, Nathan P. , Klein, Christopher J.

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.p4.019 Get It

Clinical and Electrophysiological Features of Multifocal Motor Neuropathy (P3.179)
Sorenson, Eric J. , O’Gorman, Cullen

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.p3.179 Get It

County‐Level Cardiologist Density and Mortality in the United States
Minhas, Abdul Mannan Khan , Parwani, Purvi , Fudim, Marat , Virani, Salim S. , Khan, Sadiya S. , Cullen, Michael W. , Misra, Arunima , Ballantyne, Christie M. , Nambi, Vijay , Abramov, Dmitry , Ballantyne, Christie M , Khan, Sadiya S

Journal of the American Heart Association | November 28, 2023 | Volume: 12 | Issue: 23 | Pages: No page available

10.1161/jaha.123.031686 | PMID 38014694 Get It

Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM
Petronek, Michael S. , Monga, Varun , Bodeker, Kellie L. , Kwofie, Michael , Lee, Chu‐Yu , Stolwijk, Jeffrey M. , Zaher, Amira , Wagner, Brett A. , Smith, Mark C. , Vollstedt, Sandy , Brown, Heather , Chandler, Meghan L. , Lorack, Amanda C. , Wulfekuhle, Jared S. , Flynn, Ryan T. , Jones, Karra A. , Magnotta, Vincent A. , Mapuskar, Kranti A , Stolwijk, Jeffrey M , Zaher, Amira , Wagner, Brett A , Smith, Mark C , Vollstedt, Sandy , Brown, Heather , Chandler, Meghan L , Lorack, Amanda C , Wulfekuhle, Jared S , Sarkaria, Jann N , Flynn, Ryan T , Greenlee, Jeremy D W , Howard, Matthew A , Smith, Brian J , Jones, Karra A , Buettner, Garry R , Cullen, Joseph J , St-Aubin, Joel , Buatti, John M , Magnotta, Vincent A , Spitz, Douglas R , Allen, Bryan G , Monga, Varun , Mapuskar, Kranti A. , Sarkaria, Jann N. , Greenlee, Jeremy D.W. , Howard, Matthew A. , Buettner, Garry R. , Buatti, John M. , Spitz, Douglas R.

Clinical Cancer Research | September 29, 2023 | Volume: 30 | Issue: 2 | Pages: 283-293

10.1158/1078-0432.ccr-22-3952 | PMID 37773633 Get It

Abstract Purpose: Pharmacologic ascorbate (P-AscH−) is hypothesized to be an iron (Fe)-dependent tumor-specific adjuvant to chemoradiation in treating glioblastoma (GBM). This study determined the efficacy of combining P-AscH− with radiation and temozolomide in a phase II clinical trial while simultaneously investigating a mechanism-based, noninvasive biomarker in T2* mapping to predict GBM response to P-AscH− in humans. Patients and Methods: The single-arm phase II clinical trial (NCT02344355) enrolled 55 subjects, with analysis performed 12 months following the completion of treatment. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan–Meier method and compared across patient subgroups with log-rank tests. Forty-nine of 55 subjects were evaluated using T2*-based MRI to assess its utility as an Fe-dependent biomarker. Results: Median OS was estimated to be 19.6 months [90% confidence interval (CI), 15.7–26.5 months], a statistically significant increase compared with historic control patients (14.6 months). Subjects with initial T2* relaxation < 50 ms were associated with a significant increase in PFS compared with T2*-high subjects (11.2 months vs. 5.7 months, P < 0.05) and a trend toward increased OS (26.5 months vs. 17.5 months). These results were validated in preclinical in vitro and in vivo model systems. Conclusions: P-AscH− combined with temozolomide and radiotherapy has the potential to significantly enhance GBM survival. T2*-based MRI assessment of tumor iron content is a prognostic biomarker for GBM clinical outcomes. See related commentary by Nabavizadeh and Bagley, p. 255
Combined endoscopic sinus surgery and endonasal septal perforation repair: Symptom outcomes and perforation closure rates
Leung, Sabrina , Brar, Tripti , Bansberg, Stephen F. , Marino, Michael J. , Lal, Devyani , Miglani, Amar , Leung, Sabrina W , Taylor, Cullen , Lal, Devyani , Taylor, Cullen M.

International Forum of Allergy & Rhinology | September 5, 2023 | Volume: 14 | Issue: 4 | Pages: 870-872

10.1002/alr.23265 | PMID 37669016 Get It

Key Points Combined endoscopic sinus surgery and nasal septal perforation repair is technically feasible. NOSE‐Perf is a recently developed patient‐reported outcome measure for nasal septal perforation. The decision to perform combined ESS and NSP repair should be made on a case‐by‐case basis.
Autologous Interposition Grafts for Mucosal Flap Septal Perforation Repair
Bansberg, Stephen F. , Taylor, Cullen M. , Marino, Michael J. , Courson, Andy M., Miglani, Amar , Taylor, Cullen , Courson, Andy M.

Facial Plastic Surgery & Aesthetic Medicine | June 26, 2023 | Volume: 26 | Issue: 2 | Pages: 111-116

10.1089/fpsam.2022.0179 | PMID 37358819 Get It

Background: Nasal septal perforation repair is commonly attempted utilizing bilateral nasal mucosal flaps supported with an interposition graft. Objectives: To compare the failure rates for bilateral flap repairs utilizing four different autologous interposition grafts. Methods: This is a retrospective review of a single surgeon's bilateral flap perforation repairs supported with an autologous interposition graft. Study inclusion over the 18-year review period required at least one examination 1 month after surgery. Repair failure rates were calculated and compared for each graft type, and logistic regression was performed for multivariate analysis. Results: For the 356 study patients, median (range) age was 51 years (14–81) and 63.0% were women. Mean (range) perforation length was 13.9 mm (1–45). Median (range) at last follow-up was 11.2 months (1–192). Graft types used (percentage of patients and failure rate) were temporalis fascia (58.7/4.4), septal cartilage (23.3/7.3), auricular perichondrium (13.8/4.1), and septal bone (4.2/6.7) ( p > 0.05). Conclusion: There was no significant difference in bilateral mucosal flap perforation repair failure rate when either a temporalis fascia, septal cartilage, auricular perichondrium, or septal bone interposition graft was used.
Prototheca Infection: A Descriptive Study
Cullen, Grace , Yetmar, Zachary A. , Fida, Madiha , Saleh, Omar Abu , Cullen, Grace D , Abu Saleh, Omar M, Yetmar, Zachary A , Fida, Madiha

Open Forum Infectious Diseases | June 9, 2023 | Volume: 10 | Issue: 6 | Pages: No page available

10.1093/ofid/ofad294 | PMID 37389225 Get It

Abstract Prototheca is a microalgae known to cause infections in humans, with protothecosis most commonly presenting as olecranon bursitis or localized soft tissue infection. Disseminated disease can be seen in immunocompromised patients. In this retrospective single-institution case series, we describe our experience with 7 patients with Prototheca infections.
Septal Perforation Repair Quality of Life Outcomes Using the Revised 15-item Glasgow Benefit Inventory
Taylor, Cullen M. , Marino, Michael J. , Bansberg, Stephen F. , Taylor, Cullen

Annals of Otology, Rhinology & Laryngology | May 9, 2023 | Volume: 132 | Issue: 12 | Pages: 1550-1556

10.1177/00034894231170938 | PMID 37157824 Get It

Background: The 18-item Glasgow Benefit Inventory (GBI) has been widely used to measure patient general health response to otorhinolaryngologic and facial plastic interventions. The GBI was recently reorganized into 15 questions with 5 sub-scale factors ( GBI-5F) to improve its utility. Application of the GBI-5F to septal perforation treatments may improve our understanding of quality of life outcomes. Methodology/Principal: The GBI was given to patients seen from August 2018 through October 2021 who were at least 6 months postoperative attempted perforation surgical closure using bilateral nasal mucosal flaps with an interposition graft. Original GBI and GBI-5F scores were computed and subgroup analysis performed in this retrospective medical record review. Results: Of the 98 patients (mean age 45.5 years) who met study criteria, 65 were female. Mean perforation length was 12.9, and height 9.7 mm. The mean postoperative time to GBI completion was 12.7 months. Highest GBI-5F scores were noted in the Quality of Life factor, followed by Self-confidence and Social Involvement. Females reported significantly higher scores than men. Total GBI scores were similar to those recorded for other rhinologic procedures. Conclusions: The GBI-5F provides measurable insight into patient quality of life benefit following septal perforation repair.
Murine Ia Antigens: Identification and Mapping of Ia.23 and Further Definition of the I-E Subregion
David, Chella S., Cullen, Susan E.

The Journal of Immunology | January 1, 2023 | Volume: 120 | Issue: 5 | Pages: 1659-1662

10.4049/jimmunol.120.5.1659 Get It

Abstract The Ia.23 specificity is a private specificity of the H-2d haplotype which we have assigned to the I-E subregion. It is found on the same Ia molecule that bears Ia.7, a public specificity previously assigned to the I-C subregion of haplotypes H-2d, H-2k, H-2p and H-2r. We suggest a reassignment of specificity Ia.7 to the I-E subregion to simplify the interpretation of the data presented in this paper and elsewhere, and to permit an orderly description of that part of the I region to the right of I-J.